|RxNews Recap for Thursday 12-10-09|
|By Mary Davila|
|Thursday, 10 December 2009 19:29|
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Pro-Pharmaceuticals, Inc. (OTCBB: PRWP) (the “Company”), today announced that it has closed a $325,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants.
PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced that public health information website, TouchSurfaces.org, is recommending its SDC hard surface disinfectant as a highly effective weapon in eradicating H1N1, MRSA, VRE, Norovirus and other dangerous pathogens commonly spread on hard surfaces.
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia. TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, or NNR, and was discovered by Targacept scientists using Targacept’s proprietary drug discovery platform known as PentadTM.
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 2009 DB-Biotech Boston Confab on Tuesday, December 15, 2009, at 2:35 p.m. Eastern Time.
BioReference Laboratories, Inc. (NASDAQ: BRLI) announced today it plans to issue earnings results for the fourth quarter and year end of fiscal 2009 before the open of market trading on Thursday, December 17, 2009.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Nancy J. Wysenski as Executive Vice President and Chief Commercial Office.
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today reported that the Company held a pre-NDA meeting on December 8, 2009 with the FDA to discuss the Company’s proposed new drug application (NDA) for rifaximin in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).
Enzo Biochem, Inc. (NYSE:ENZ) announced today that its Enzo Clinical Lab division has entered into an exclusive marketing partnership covering the States of New York and New Jersey with privately-owned Ikonisys, Inc., of New Haven, CT, relating to Ikonisys’ proprietary oncoFISH® cervical test, a laboratory developed test for cervical cancer prevention.
Lannett Company, Inc. (NYSE AMEX: LCI) today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Hydromorphone Hydrochloride Tablets USP, 2 mg, 4 mg and 8 mg, the generic equivalent of Purdue Pharmaceuticals’ (formerly Abbott’s) Dilaudid® Tablets 2 mg, 4 mg and 8 mg.
Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, today reported for the fiscal first quarter ended October 31, 2009, record operating revenues and sharply improved operating results.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has recommended that aztreonam for inhalation solution be approved for the treatment of infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF).
Deltagen, Inc. (Pink Sheets:DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended September 30, 2009.
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that it received a notice on December 9, 2009 from the NASDAQ Stock Market indicating that the Company no longer meets the minimum bid price requirement for continued listing on the NASDAQ Global Market as set forth in Marketplace Rule 5450(a)(1).
Unigene Laboratories, Inc. (OTCBB: UGNE) announced that an independent Data Monitoring Committee (DMC) has recommended that Novartis and its partner Nordic Bioscience proceed as planned with their ongoing oral calcitonin Phase III studies for osteoporosis and osteoarthritis.
Biogen Idec (NASDAQ:BIIB) today announced that William D. Young will become Chairman of the Company’s Board of Directors, effective January 1, 2010. The appointment follows the decision by Bruce R. Ross, 68, the Company’s Chairman since December 2005, to step down as Chairman, effective January 1, 2010.